DE2551280A1 - L-dopa-zubereitung - Google Patents

L-dopa-zubereitung

Info

Publication number
DE2551280A1
DE2551280A1 DE19752551280 DE2551280A DE2551280A1 DE 2551280 A1 DE2551280 A1 DE 2551280A1 DE 19752551280 DE19752551280 DE 19752551280 DE 2551280 A DE2551280 A DE 2551280A DE 2551280 A1 DE2551280 A1 DE 2551280A1
Authority
DE
Germany
Prior art keywords
dopa
phenylalanine
diacetyloxy
coating
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19752551280
Other languages
German (de)
English (en)
Inventor
Mikio Arai
Kenji Nishimura
Takashi Nitanai
Kunihiro Sasahara
Kanagawa Yokohama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE2551280A1 publication Critical patent/DE2551280A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE19752551280 1974-11-14 1975-11-14 L-dopa-zubereitung Withdrawn DE2551280A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP49131304A JPS5157813A (en) 1974-11-14 1974-11-14 Ll dooba mataha sonojudotaiseizaino seiho

Publications (1)

Publication Number Publication Date
DE2551280A1 true DE2551280A1 (de) 1976-05-20

Family

ID=15054818

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19752551280 Withdrawn DE2551280A1 (de) 1974-11-14 1975-11-14 L-dopa-zubereitung

Country Status (10)

Country Link
US (1) US3961041A (enExample)
JP (1) JPS5157813A (enExample)
CA (1) CA1047928A (enExample)
DE (1) DE2551280A1 (enExample)
ES (1) ES442579A1 (enExample)
FR (1) FR2290912A1 (enExample)
GB (1) GB1485676A (enExample)
IT (1) IT1069069B (enExample)
NL (1) NL7513370A (enExample)
SE (1) SE7512740L (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147768A (en) * 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
JPS54138128A (en) * 1978-04-19 1979-10-26 Akiyama Jiyouzai Kk Double contrast medium for intestine
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB2130087A (en) * 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
JP2001515855A (ja) * 1997-09-09 2001-09-25 アルザ・コーポレーション 薬剤コーティング組成物と使用方法
DE69910183T2 (de) * 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE69942205D1 (de) * 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
NZ512030A (en) 1998-11-10 2003-10-31 Teva Pharma Process for manufacture of L-dopa ethyl ester
CA2350304A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
KR100299562B1 (ko) 1998-12-29 2001-11-22 우재영 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립
AU2005202472B2 (en) * 1999-04-29 2008-12-18 Cima Labs Inc. Effervescent drug delivery system for oral administration
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
CA2548915C (en) * 2003-12-31 2012-10-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
MXPA06007453A (es) * 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
JP2016029034A (ja) * 2014-07-18 2016-03-03 ナノメガ メディカル コーポレイションＮａｎｏｍｅｇａ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 医薬組成物
JP2017203031A (ja) * 2017-07-12 2017-11-16 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ ｐＨ制御パルス送達システム、その調製法及び使用法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
FR2116256A1 (en) 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa

Also Published As

Publication number Publication date
IT1069069B (it) 1985-03-25
FR2290912B1 (enExample) 1978-07-28
JPS5436645B2 (enExample) 1979-11-10
JPS5157813A (en) 1976-05-20
CA1047928A (en) 1979-02-06
GB1485676A (en) 1977-09-14
SE7512740L (sv) 1976-05-17
US3961041A (en) 1976-06-01
FR2290912A1 (fr) 1976-06-11
NL7513370A (nl) 1976-05-18
ES442579A1 (es) 1978-01-16

Similar Documents

Publication Publication Date Title
DE2551280A1 (de) L-dopa-zubereitung
DE69623634T2 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
DE69212879T2 (de) Magensaftstabile pharmazeutische Formulierungen zur Oral Verbreichung von Gallensäuren
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69802543T2 (de) Verbesserte multipartikel-tablette mit schnellauflösbarkeit
DE69727922T2 (de) Schnell zerfallende orale dosierungsform
DE3875705T2 (de) Carbidopa-levodopa-zusammensetzung mit gesteuerter freigabe.
DE69836424T2 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DE69006684T2 (de) Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.
DE69922964T2 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
DE3779933T2 (de) Xanthangummienthaltende arzneimittelformulierung mit verzoegerter freisetzung.
DE69212882T2 (de) Gallensäuresalze enthaltende magenstabile pharmazeutische Zusammensetzung zur oralen Verabreichung
DE69213800T2 (de) Oral anzuwendende magensaftstabile Arzneimittel mit gesteuerter Wirkstoffabgabe enthaltend Gallensäuren und deren Salze
AT403988B (de) Festes orales retardpräparat
EP2477660B1 (de) Pharmazeutische zusammensetzung mit den wirkstoffen metformin und sitagliptin oder vildagliptin
DE69530759T2 (de) Filmbeschichtete tablette, die paracetamol und domperidone enthält
DE202006018608U1 (de) Buprenorphin-Wafer zur Drogensubstitutionstherapie
DE3115086A1 (de) "dextromethorphan enthaltende pharamzeutische zusammensetzung und die verwendung von dextromethorphan zur schmerzbekaempfung"
DE69814850T2 (de) Paracetamol enthaltende schlickbare tablette
EP1509207B1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
DE69205158T2 (de) Essbare pharmazeutische zusammensetzungen zur behandlung von verdauungstraktschmerzen.
DE60225686T2 (de) Paracetamol enthaltende tablette
DE3834794A1 (de) Oral zu verabreichendes mittel zur behandlung von psoriasis
WO1999024023A2 (de) FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG
DE69817379T2 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne

Legal Events

Date Code Title Description
OD Request for examination
8125 Change of the main classification
8130 Withdrawal